Pfizer (PFE) Earnings Date & Reports

Key Takeaways

• Q2 2026 earnings are scheduled for release on Tuesday, August 4, before the market opens, with a conference call at 10:00 a.m. EDT.
• Wall Street consensus anticipates adjusted earnings per share (EPS) of $0.68, representing a 12.8% decline from $0.78 in the same quarter last year.
• Revenue is expected to come in near $14.45 billion, down approximately 1.4% year-over-year, as pandemic-era product sales continue to normalize.
• Pfizer has beaten EPS estimates in each of the last four quarters, raising the bar for another potential upside surprise.
• A July 10 FDA approval expanded the Padcev-Keytruda bladder cancer indication, adding a fresh catalyst to the oncology narrative heading into the report.
• This marks CFO Dave Denton's final earnings call before his August 15 departure, making the tone and framing of full-year guidance particularly significant.

Earnings Context and Why It Matters

Pfizer's second-quarter report lands at a pivotal moment for the pharmaceutical giant. With a market capitalization near $142 billion and shares trading around $25 — not far above the 52-week low of approximately $23 — investor sentiment remains cautious. The company is navigating a delicate transition: COVID-19 product revenues from Comirnaty and Paxlovid are structurally declining, while its oncology franchise, bolstered by the $43 billion Seagen acquisition, must prove it can deliver enough growth to fill the gap. Adding weight to this particular report, Pfizer recently secured an expanded FDA approval for Padcev (enfortumab vedotin-ejfv) in muscle-invasive bladder cancer on July 10, giving management a tangible win to discuss. Meanwhile, looming patent expirations on blockbuster drugs such as Eliquis and Ibrance keep long-term revenue durability firmly in the spotlight.

Earnings Expectations

Analysts have set the bar at adjusted EPS of $0.68 on revenue of approximately $14.45 billion for the second quarter of fiscal 2026. Both figures represent year-over-year declines — roughly 13% on the bottom line and just under 2% on the top line — reflecting the ongoing erosion of COVID-related sales. For context, in the year-ago quarter Pfizer posted EPS of $0.78 on revenue of $14.65 billion.

Several individual product lines will draw outsized attention. Consensus estimates place alliance revenues from the blood thinner Eliquis at approximately $1.98 billion, while the Prevnar vaccine family is expected to contribute roughly $1.39 billion. On the COVID front, Comirnaty direct sales and alliance revenues are pegged near $278 million (down 27% year-over-year), and Paxlovid is forecast to generate only around $119 million (down roughly 72%). The transthyretin amyloidosis treatment Vyndaqel/Vyndamax is expected to remain a bright spot, with consensus near $1.75 billion. RBC Capital Markets recently cautioned that EPS could come in closer to $0.66, citing an unfavorable gross margin mix and elevated R&D (research and development) spending to support pipeline programs.

Pfizer's full-year 2026 guidance, reaffirmed in May, calls for revenue of $59.5 billion to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00. Whether management raises, trims, or simply reaffirms that range will likely be the single most consequential element of the August 4 release.

AI Screener

For investors looking to identify opportunities beyond individual earnings reports, Tickeron's AI Screener offers a powerful AI-driven platform that helps traders and investors filter thousands of stocks and ETFs (exchange-traded funds) using customizable criteria such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener scans for breakout candidates, trending stocks, and emerging trade ideas based on technical patterns, fundamental data, volatility profiles, and AI-generated signals — all designed to streamline the research process and surface opportunities more efficiently than manual screening. For those seeking to complement their earnings-season analysis with broader market discovery, the AI Screener is a practical starting point.

Market Reaction and Investor Sentiment

Heading into the Q2 release, Pfizer shares have been stuck in a tight trading range, closing July near $25 and underperforming the broader healthcare sector this year. The stock currently carries a consensus "Hold" rating from analysts, with an average 12-month price target of approximately $28.50, implying roughly 14% upside from current levels. The forward price-to-earnings (P/E) ratio sits near 8.5x — a steep discount to the large-cap pharmaceutical peer average — suggesting the market has already priced in a business in mild decline.

Investor sentiment remains divided. Bulls point to Pfizer's attractive dividend yield near 6.9%, the growing oncology franchise, and low valuation as compelling reasons to stay. Bears highlight the persistent revenue drag from COVID products, looming patent cliffs on Eliquis and Ibrance, and the late-June setback when sigvotatug vedotin missed its overall survival endpoint in second-line lung cancer. The stock rose only marginally following the Q1 beat in May, indicating that investors need more than a modest upside surprise to re-rate shares higher. This quarter, the guidance framework — particularly management's $5 billion full-year COVID revenue assumption — will likely matter more than the headline numbers themselves.

Forward Outlook and Key Factors to Monitor

Beyond the immediate Q2 results, three interconnected themes will shape Pfizer's trajectory through the remainder of 2026 and into 2027.

First, the oncology pipeline must continue delivering. The expanded Padcev approval in July was a meaningful step, and investors will look for confirmation that Seagen-acquired products are maintaining commercial momentum. Upcoming regulatory decisions — including the FDA's expected ruling on the Talzenna-Xtandi combination for prostate cancer — represent additional catalysts. At the same time, the sigvotatug vedotin miss in June serves as a reminder that pipeline setbacks remain a real risk, even for a company of Pfizer's scale.

Second, cost discipline and margin execution are becoming increasingly important. Pfizer's manufacturing optimization program targets approximately $7.2 billion in total net savings by the end of 2026, with Phase I expected to deliver roughly $700 million this year. How those savings flow through to operating margins will directly affect earnings quality as revenue growth remains under pressure.

Third, the patent cliff timeline demands attention. With Eliquis and Ibrance facing loss of exclusivity in the coming years, the company's ability to offset those declines through new launches, label expansions, and business development activity will determine whether Pfizer can transition from a defensive yield play to a genuine growth story. CEO Albert Bourla has pointed to a high single-digit revenue compound annual growth rate (CAGR) beginning in 2029. For now, investors will be watching whether the second quarter's underlying non-COVID growth — which ran at approximately 7% operationally in Q1 — can sustain that trajectory.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations